Charles Schwab Investment Management Inc. Acquires 1,092 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Charles Schwab Investment Management Inc. raised its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 0.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 167,021 shares of the company’s stock after purchasing an additional 1,092 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.56% of Dianthus Therapeutics worth $3,641,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. R Squared Ltd acquired a new stake in shares of Dianthus Therapeutics in the fourth quarter valued at $26,000. Quest Partners LLC increased its position in Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. KBC Group NV bought a new position in shares of Dianthus Therapeutics in the fourth quarter worth about $35,000. SG Americas Securities LLC lifted its position in shares of Dianthus Therapeutics by 9.2% during the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company’s stock worth $210,000 after purchasing an additional 814 shares in the last quarter. Finally, Fred Alger Management LLC grew its stake in shares of Dianthus Therapeutics by 52.5% during the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock valued at $264,000 after purchasing an additional 3,316 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Wall Street Analyst Weigh In

DNTH has been the subject of several research analyst reports. Guggenheim reaffirmed a “buy” rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. TD Cowen initiated coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating on the stock. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Wedbush restated an “outperform” rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $54.33.

Dianthus Therapeutics Price Performance

Shares of DNTH stock opened at $18.27 on Thursday. The stock has a market cap of $586.92 million, a PE ratio of -7.31 and a beta of 1.82. The stock has a 50-day moving average of $21.90 and a 200-day moving average of $24.37. Dianthus Therapeutics, Inc. has a one year low of $17.50 and a one year high of $32.29.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.04. The firm had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.